Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1622 1624 1626 1629 1787
This examiner grants 79% of resolved cases
Bruck Kifle is an examiner in Tech Center 1700 and Art Unit 1622, where he has overseen 1738 resolved cases. The allowance rate of 79.2 indicates the frequency of successful outcomes for applications. The median days to allowance stands at 669, which provides a timeline for resolution that practitioners can factor into their prosecution strategy. This duration is a benchmark for managing expectations regarding the speed of the patent grant process.
The data shows an interview lift of 15.9, which represents the increase in the likelihood of allowance when an interview is conducted. Given the volume of 1738 resolved cases, these metrics provide a baseline for predicting examiner behavior. Practitioners can use the 15.9 lift to evaluate the impact of requesting an interview to improve upon the 79.2 allowance rate. The combination of the case volume and the 669-day median pendency defines the prosecution experience with this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18770318 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Deciphera Pharmaceuticals, LLC |
| 17789113 | METHOD FOR MANUFACTURING 1,3-BUTYLENE GLYCOL, AND 1,3-BUTYLENE GLYCOL PRODUCT | Non-Final OA | DAICEL CORPORATION |
| 18218325 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18715470 | FUNGICIDAL COMPOSITIONS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18551314 | USE OF OXYMETHYL-MODIFIED DERIVATIVE OF QUERCETIN IN PREPARATION OF DRUG FOR INHIBITING TUMOR CELL PROLIFERATION | Final Rejection | ZHEJIANG UNIVERSITY |
| 18599116 | COMPOUNDS AND THE USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Final Rejection | Lemon Inc. |
| 18938633 | MCL1 INHIBITORS | Non-Final OA | Gilead Sciences, Inc. |
| 18918629 | MCL-1 INHIBITORS | Non-Final OA | Gilead Sciences, Inc. |
| 18954736 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | Non-Final OA | Pfizer Inc. |
| 18757200 | IRE1 SMALL MOLECULE INHIBITORS | Non-Final OA | Cornell University |
| 18638034 | CYCLIC UREA KRAS INHIBITORS | Final Rejection | INCYTE CORPORATION |
| 18209751 | METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE AND COMPOSITION | Final Rejection | JSR CORPORATION |
| 18866978 | NOVEL METHODS | Non-Final OA | INTRA-CELLULAR THERAPIES, INC. |
| 18860392 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | Non-Final OA | UEA ENTERPRISES LIMITED |
| 18882884 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Non-Final OA | Agios Pharmaceuticals, Inc. |
| 18776612 | MASP-2 INHIBITORS AND METHODS OF USE | Final Rejection | Omeros Corporation |
| 18777239 | MASP-2 INHIBITORS AND METHODS OF USE | Final Rejection | Omeros Corporation |
| 18730071 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy